Boceprevir and personalized medicine in hepatitis C virus infection

References

• ChooQLKuoGWeinerAJOverbyLRBradleyDWHoughtonMIsolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genomeScience19892443593622523562
   PubMed Web of Science ®Google Scholar
• LauerGMWalkerBDHepatitis C virus infectionN Engl J Med2001345415211439948
   PubMed Web of Science ®Google Scholar
• World Health Organization Hepatitis C. Fact sheet N°164. July 2012. [Webpage on the Internet] http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed April 14, 2012.
   Google Scholar
• ArmstrongGLWasleyASimardEPMcQuillanGMKuhnertWLAlterMJThe prevalence of hepatitis C virus infection in the United States, 1999 through 2002Ann Intern Med200614470571416702586
   PubMed Web of Science ®Google Scholar
• MoradpourDPeninFRiceCMReplication of hepatitis C virusNat Rev Microbiol2007545346317487147
   PubMed Web of Science ®Google Scholar
• SeeffLBNatural history of chronic hepatitis CHepatology2002365 Suppl 1S35S4612407575
   PubMed Web of Science ®Google Scholar
• GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of hepatitis C: an updateHepatology2009491335137419330875
   PubMed Web of Science ®Google Scholar
• HoofnagleJHMullenKDJonesDBTreatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary reportN Engl J Med1986315157515783097544
   PubMed Web of Science ®Google Scholar
• ShiratoriYImazekiFMoriyamaMHistologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapyAnn Intern Med200013251752410744587
   PubMed Web of Science ®Google Scholar
• ImaiYKasaharaATanakaHInterferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical responseJ Gastroenterol2004391069107715580400
   PubMed Web of Science ®Google Scholar
• KasaharaATanakaHOkanoueTInterferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related deathJ Viral Hepat20041114815614996350
   PubMed Web of Science ®Google Scholar
• KatzeMGHeYGaleMJrViruses and interferon: a fight for supremacyNat Rev Immunol2002267568712209136
   PubMed Web of Science ®Google Scholar
• PawlotskyJMTherapy of hepatitis C: From empiricism to eradicationHepatology200643Suppl 1S207S22016447262
   PubMed Web of Science ®Google Scholar
• ReichardOAnderssonJSchvarczRWeilandORibavirin treatment for chronic hepatitis CLancet1991337105810611673493
   PubMed Web of Science ®Google Scholar
• Di BisceglieAMShindoMFongTLA pilot study of ribavirin therapy for chronic hepatitis CHepatology1992166496541505907
   PubMed Web of Science ®Google Scholar
• BrillantiSGarsonJFoliMA pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis CGastroenterology19941078128177521308
   PubMed Web of Science ®Google Scholar
• PoynardTMarcellinPLeeSSRandomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Lancet1998352142614329807989
   PubMed Web of Science ®Google Scholar
• LohmannVKörnerFKochJHerianUTheilmannIBartenschlagerRReplication of subgenomic hepatitis C virus RNAs in a hepatoma cell lineScience199928511011310390360
   PubMed Web of Science ®Google Scholar
• LindenbachBDRiceCMFlaviviridae: The viruses and their replicationFields Virology Volume 14th edPhiladelphia, PALippincott Williams & Wilkins2001
   Google Scholar
• KimJLMorgensternKALinCCrystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptideCell1996873433558861917
   PubMed Web of Science ®Google Scholar
• LoveRAPargeHEWickershamJAThe crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding siteCell1996873313428861916
   PubMed Web of Science ®Google Scholar
• LamarreDAndersonPCBaileyMAn NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusNature200342618618914578911
   PubMed Web of Science ®Google Scholar
• MalcolmBALiuRLahserFSCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cellsAntimicrob Agents Chemother2006501013102016495264
   PubMed Web of Science ®Google Scholar
• Merck. Victrelis (boceprevir) prescribing information. May 2011. Available at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Accessed July 10, 2012.
   Google Scholar
• FDA US Food and Drug AdministrationDrug approval package Victrelis (boceprevir). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000TOC.cfm. Accessed December 14, 2011.
   Google Scholar
• GhosalAYuanYTongWCharacterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitorDrug Metab Dispos20113951052121123164
   PubMed Web of Science ®Google Scholar
• FlockhartDATanus-SantosJEImplications of cytochrome P450 interactions when prescribing medication for hypertensionArch Intern Med200216240541211863472
   PubMed Web of Science ®Google Scholar
• KiserJJBurtonJRAndersonPLEversonGTReview and management of drug interactions with boceprevir and telaprevirHepatology2012551620162822331658
   PubMed Web of Science ®Google Scholar
• ZeuzemSSarrazinCRouzierRAntiviral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-alpha)Hepatology200542Suppl 1S233S234
   Google Scholar
• SusserSWelkerMWZettlerMClonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH503034)J Hepatol200848Suppl 2S29
   Web of Science ®Google Scholar
• FlintMMullenSDeatlyAMSelection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)Antimicrob Agents Chemother20095340141118936191
   PubMed Web of Science ®Google Scholar
• PawlotskyJMTreatment of hepatitis C: don’t put all your eggs in one basket!Gastroenterology20071321611161517418174
   PubMed Web of Science ®Google Scholar
• SarrazinCRouzierRWagnerFSCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersGastroenterology20071321270127817408662
   PubMed Web of Science ®Google Scholar
• KwoPYLawitzEJMcConeJEfficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialLancet201037670571620692693
   PubMed Web of Science ®Google Scholar
• SchiffEPoordadFJacobsonIBoceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsivenessJ Hepatol200848Suppl 2S46
   Web of Science ®Google Scholar
• PoordadFMcConeJBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med20113641195120621449783
   PubMed Web of Science ®Google Scholar
• BaconBRGordonSCLawitzEBoceprevir for previously treated chronic HCV genotype 1 infectionN Engl J Med20113641207121721449784
   PubMed Web of Science ®Google Scholar
• BrassCBarnardRJOHoweJASustained virologic response and boceprevir resistance-associated variants observed in patients infected with HCV genotype 1a/1b when treated with boceprevir plus peginterferon alfa-2b/ribavirinJ Hepatol201154Suppl 1S471S472
   Web of Science ®Google Scholar
• BronowickiJPDavisMFlammSSustained virologic response (SVR) in prior peginterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)-+-PR: the provide study interim resultsJ Hepatol201256Suppl 2S6
   Web of Science ®Google Scholar
• VierlingJMRalstonRLawitzEJLong-term outcomes following combination treatment with boceprevir plus peg-intron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1)J Hepatol201052Suppl 1S470S471
   Web of Science ®Google Scholar
• JacobsonIMMarcellinPZeuzemSRefinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir combined with peginterferon/ribavirinHepatology5222012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• ConjeevaramHSFriedMWJeffersLJPeginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Gastroenterology200613147047716890601
   PubMed Web of Science ®Google Scholar
• GeDFellayJThompsonAJGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature200946139940119684573
   PubMed Web of Science ®Google Scholar
• ThomasDLThioCLMartinMPGenetic variation in IL28B and spontaneous clearance of hepatitis C virusNature200946179880119759533
   PubMed Web of Science ®Google Scholar
• ThompsonAJMuirAJSulkowskiMSInterleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virusGastroenterology201013912012920399780
   PubMed Web of Science ®Google Scholar
• PoordadFBronowickiJPGordonSCFactors that predict response of patients with hepatitis C virus infection to boceprevirGastroenterology5212012 [Epub ahead of print.]
   Web of Science ®Google Scholar
• KwoPYPhase III results in genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirinLiver Int201232Suppl 1S39S43
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med200234797598212324553
   PubMed Web of Science ®Google Scholar
• FellayJThompsonAGeDITPA gene variants protect against anaemia in patients treated for chronic hepatitis CNature201046440540820173735
   PubMed Web of Science ®Google Scholar
• ThompsonAJFellayJPatelKVariants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionGastroenterology20101391181118920547162
   PubMed Web of Science ®Google Scholar
• PoordadFLawitzEJReddyKRA randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirinJ Hepatol201256Suppl 2S559
   Web of Science ®Google Scholar
• Golden-MasonLKlarquistJWahedASRosenHRCutting edge: Programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differencesJ Immunol20081803637364118322167
   PubMed Web of Science ®Google Scholar
• UrbaniSAmadeiBTolaDPD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustionJ Virol200680113981140316956940
   PubMed Web of Science ®Google Scholar
• Vidal-CastiñeiraJRLópez-VázquezAAlonso-AriasRA predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotypingJ Hepatol2012561230123822322230
   PubMed Web of Science ®Google Scholar
• SulkowskiMPolSCooperCBoceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim resultsAbstract 47 presented at the 19th Conference on Retroviruses and Opportunistic InfectionsSeattle, WAMarch 5–8, 2012.
   Google Scholar
• RamachandranPFraserAAgarwalKUK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patientsAliment Pharmacol Ther20123564766222296568
   PubMed Web of Science ®Google Scholar
• IwasakiYIkedaHArakiYLimitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis CHepatology200643546316374855
   PubMed Web of Science ®Google Scholar
• LawitzEPoordadFKowdleyKVA 12-week interferon-free regimen of ABT-450/R, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% of treatment-naive HCV IL28B-CC genotype-1-infected subjectsJ Hepatol201256Suppl 2S7
   Web of Science ®Google Scholar
• SulkowskiMRodriguez-TorresMLawitzEHigh SVR rate in treatment-naïve HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim resultsJ Hepatol201256Suppl 2S559
   Google Scholar
• Approval of Victrelis (boceprevir) by US Food and Drug Administration. May 2011. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.htm. Accessed July 10, 2012.
   Google Scholar
• BarrittASFriedMWMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusGastroenterology2012141314132322537438
   PubMed Web of Science ®Google Scholar
• KlibanovOMVickerySBOlinJLBoceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis CPharmacotherapy20123217319022392426
   PubMed Web of Science ®Google Scholar
• HulkotteEGuptaSXuanFPharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteersHepatology5112012 [Epub ahead of print.]
   Web of Science ®Google Scholar